myasthenia


Also found in: Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to myasthenia: Ocular myasthenia

my·as·the·ni·a

 (mī′əs-thē′nē-ə)
n.
1. Abnormal muscular weakness or fatigue.
2. Myasthenia gravis.

my′as·then′ic (-thĕn′ĭk) adj.

myasthenia

(ˌmaɪəsˈθiːnɪə)
n
1. (Pathology) any muscular weakness
2. (Pathology) short for myasthenia gravis
[C19: from myo- + asthenia]
myasthenic adj

my•as•the•ni•a

(ˌmaɪ əsˈθi ni ə)

n.
muscle weakness.
[1855–60]
my`as•then′ic (-ˈθɛn ɪk) adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myasthenia - a chronic progressive disease characterized by chronic fatigue and muscular weakness (especially in the face and neck); caused by a deficiency of acetylcholine at the neuromuscular junctions
disease of the neuromuscular junction - a disease characterized by impairment of neuromuscular junctions
autoimmune disease, autoimmune disorder - any of a large group of diseases characterized by abnormal functioning of the immune system that causes your immune system to produce antibodies against your own tissues
2.myasthenia - any muscular weakness
physical condition, physiological condition, physiological state - the condition or state of the body or bodily functions
Translations

my·as·the·ni·a

n. miastenia, debilidad muscular;
___ gravis___ grave.
References in periodicals archive ?
M2 PHARMA-December 22, 2017-Ra Pharmaceuticals Starts Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalised Myasthenia Gravis Patients
Data from Argenx's (EBR: ARGX) Phase 2 proof-of-concept clinical trial of ARGX-113 (efgartigimod) in myasthenia gravis (MG) patients with confirmed generalised muscle weakness has seen positive top-line results, the company announced on Monday.
This information is inaccurate because, although myasthenia gravis is an exclusion criterion, Wolfe et al.
Myasthenia gravis (MG) is a disease affecting the acetylcholine receptor in the neuromuscular junction.
The case presented here is about unmasking of myasthenia gravis in a patient who received alfa interferon therapy for her chronic hepatitis C.
The most common of such conditions is myasthenia gravis (MG), an autoimmune disorder in which an antibody-mediated, T-cell-dependent process targets acetylcholine receptors on the postsynaptic membrane of the neuromuscular junction.
Canada, April 4, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.
OTTAWA, Ont, Canada, April 18, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.
OTTAWA, Ont, Canada, April 4, 2016 -- A Canadian report on seven cases of severe myasthenia gravis suggests that autologous hematopoietic stem cell transplantation (using a patient's own stem cells) may result in long-term remission that is symptom and treatment free, according to a new study.
com)-- The Myasthenia Gravis Foundation of America, the New York-based nonprofit dedicated to raising research funds for and awareness of the neuromuscular disease myasthenia gravis (MG), has announced that its annual national conference planned in Raleigh, North Carolina, on May 1-3, at the Sheraton Raleigh Hotel, will not be impacted, and the organization will keep its commitment to those affected by MG by having the conference as planned, despite the MGFA's opposition to North Carolina's House Bill 2, which discriminates against the LGBT community.
USPRwire, Sun Apr 03 2016] Global Markets Direct's, 'Myasthenia Gravis - Pipeline Review, H1 2016', provides an overview of the Myasthenia Gravis pipeline landscape.
a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of an investigator-sponsored, adequate and well-controlled clinical trial evaluating safety, tolerability and efficacy of Firdapse (amifampridine phosphate) as a symptomatic treatment for patients with MuSK-antibody positive myasthenia gravis (MuSK-MG).